Description du projet
L’IA pour guider le traitement de la drépanocytose
La drépanocytose est une maladie génétique qui affecte la fonction des globules rouges, entraînant un défaut d’approvisionnement en oxygène de tous les organes. Bien qu’il existe certains traitements efficaces qui réduisent les symptômes de la maladie, la prise de décision est difficile et insuffisamment encadrée. La mission du projet INNOVHEM, financé par l’UE, est d’améliorer les soins cliniques prodigués aux patients atteints de drépanocytose et d’améliorer leur qualité de vie. Pour ce faire, les chercheurs développent une solution d’intelligence artificielle (IA) qui prend en compte les paramètres biologiques et cliniques de la maladie pour aider les médecins à proposer un plan de traitement personnalisé.
Objectif
INNOVHEM is a french start-up that has been incorporated in October 2019 which develops new and relevant diagnostic tools to tackle Sickle cell disease. Sickle Cell Disease is a very severe disease and is the most frequent genetic disease over the world, affecting around 5 million people. Despite this disease has been discovered at the beginning of the 20th century, there is still several unmet needs to tackle it.
In resource-poor countries, about 90% of children are estimated to die before the age of 5. In Europe, more than 60 000 people are affected. Their life expectency is shortened to around 45 years old and 80% of physicians say that they lack support tools for treatment decision. In addition, SCD is associated to high clinical costs. At INNOVHEM, we are developing a solution which is a combination of biomarkers, specifically adapted to the physiopathology of the disease, with articial intelligence. This solution will help the physicians to propose a personalized medical care to the patients and it will also help the development of new effective treatments. This will deeply improve health of Sickle cell patients. As an example of impacts, one of the short-term goals is to avoid 20% of emergency visits, this sole effect will save $ 30 million / year in Europe.
During the first year of activity, INNOVHEM showed a high commercial traction, that allows to sign contracts for a total amonut of 800k euros . We also enter into several partnerships with leading clinical and university centers for sickle cell disease.
Our mission is to improve clinical care of Sickle cell patients and improve their lives. A financial support will help us to build our access market strategy and our growth in Europe.
Programme(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Appel à propositions
(s’ouvre dans une nouvelle fenêtre) HORIZON-EIE-2021-SCALEUP-01
Voir d’autres projets de cet appelRégime de financement
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinateur
91000 Evry-Courcouronnes
France